Fewer dentist visits hit Invisalign maker Align last year. Here's why the stock is rallying now.
By Bill Peters
First-quarter, full-year forecasts top expectations
Shares of Align Technology Inc. jumped after hours Wednesday on an upbeat sales outlook, following an uptick in revenue for the company's Invisalign teeth-alignment system.
The company made that forecast after it expressed concerns about demand last year, after fewer patients went to the dentist and higher prices for basic essentials left them with less money to spend elsewhere. They also follow rival SmileDirectClub's announcement last month that it was closing up shop.
Align said it expected first-quarter sales of $960 million to $980 million, above the FactSet consensus forecast for $947 million. For the full year, the company expected sales to be "up mid-single digits" year over year, compared with FactSet expectations for around 4% growth.
Shares jumped 10.3% after hours.
Invisalign treatment involves a visit to the doctor, a 3-D scan of the patient's teeth, and clear aligners to help straighten them out. Align sells most of its products to orthodontists and dental labs, according to its annual report.
For its fourth quarter, Align reported $956.7 million in sales, up 6.1% year over year and above Wall Street's expectations for $934 million.
The company reported net income of $124 million, or $1.64 a share, up from $41.8 million, or $1.73 a share, in the same quarter that ended in 2022. Adjusted earnings per share were $2.42 for the quarter, above the consensus estimate of $2.18.
In a statement on Wednesday, Align Chief Executive Joe Hogan said the fourth-quarter results reflected greater Invisalign demand for adults and teens, and growth in Canada and Europe, the Middle East and Africa.
Sales for the company's clear teeth aligners were $781.9 million, up 6.9% year over year. However, shipments for those aligners during the quarter fell 0.6%.
In October, when Align Technology reported third-quarter results, Hogan had said that demand was lower than expected.
"Dental practices and industry research firms have reported deteriorating trends, including decreased patient visits and increased patient appointment cancellations, along with fewer orthodontic case starts overall, especially among adult patients," he said then.
The company on Wednesday also unveiled a new scanner that it said could more quickly and accurately capture the contours of the inside of someone's mouth.
Shares of Align are down 5.4% over the past 12 months.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-31-24 1736ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month